In combination with Roche’s PD-L1 blocker Tecentriq, zanzalintinib bested Bayer’s Stivarga. Exelixis is positioning the drug ...

Cabozantinib is a potent inhibitor of RTKs, including MET, VEGFR2, and RET. 10,11 In preclinical studies, cabozantinib exhibited significant antiangiogenic and antitumor activity in a broad range of ...

The data will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting during Oral Abstract Session: Head and Neck Cancer on Friday, June 3 beginning at 2:45 p.m. CT.

CONTACT-02 randomized 507 mCRPC patients 1:1 to receive either oral cabozantinib once daily plus IV atezolizumab every 3 weeks or second-line NHT with either oral abiraterone plus prednisone or ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine ...

HAYWARD, Calif., June 01, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...

Researchers randomly assigned 323 patients to 240 mg IV nivolumab every 2 weeks plus 40 mg oral cabozantinib daily. The other 328 patients received 50 mg oral sunitinib daily in a 4-weeks-on, 2 ...

HAYWARD, Calif., April 23, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

In the phase 3 trial (Clinicaltrial.gov NCT04446117), investigators randomly assigned 507 patients who had progressed on their first novel hormone therapy to receive oral cabozantinib (40 mg QD ...

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine ...